Mark Wunderlich
Overview
Explore the profile of Mark Wunderlich including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
99
Citations
5813
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Fan C, Wunderlich M, Cai X, Yan Z, Zhang F, Davis A, et al.
Leukemia
. 2023 Aug;
37(10):2073-2081.
PMID: 37532788
mTOR, as a serine/threonine kinase, is a widely pursued anticancer target. Multiple clinical trials of mTOR kinase inhibitors are ongoing, but their specificity and safety features remain lacking. Here, we...
12.
Dean S, Ishikawa C, Zhu X, Walulik S, Nixon T, Jordan J, et al.
Blood Adv
. 2023 May;
7(17):4822-4837.
PMID: 37205848
Acute myeloid leukemia (AML) is an aggressive blood cancer that stems from the rapid expansion of immature leukemic blasts in the bone marrow. Mutations in epigenetic factors represent the largest...
13.
Bennett J, Ishikawa C, Agarwal P, Yeung J, Sampson A, Uible E, et al.
Blood
. 2023 May;
142(11):989-1007.
PMID: 37172199
Dysregulation of innate immune signaling is a hallmark of hematologic malignancies. Recent therapeutic efforts to subvert aberrant innate immune signaling in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) have...
14.
Bouffi C, Wikenheiser-Brokamp K, Chaturvedi P, Sundaram N, Goddard G, Wunderlich M, et al.
Nat Biotechnol
. 2023 Jan;
41(6):824-831.
PMID: 36702898
Human intestinal organoids (HIOs) derived from pluripotent stem cells provide a valuable model for investigating human intestinal organogenesis and physiology, but they lack the immune components required to fully recapitulate...
15.
Han L, Dong L, Leung K, Zhao Z, Li Y, Gao L, et al.
Cell Stem Cell
. 2023 Jan;
30(1):52-68.e13.
PMID: 36608679
N-methyladenosine (mA), the most prevalent internal modification in mammalian mRNAs, is involved in many pathological processes. METTL16 is a recently identified mA methyltransferase. However, its role in leukemia has yet...
16.
Liu X, Sato N, Yabushita T, Li J, Jia Y, Tamura M, et al.
EMBO Mol Med
. 2022 Dec;
15(1):e15631.
PMID: 36453131
Inosine monophosphate dehydrogenase (IMPDH) is a rate-limiting enzyme in de novo guanine nucleotide synthesis pathway. Although IMPDH inhibitors are widely used as effective immunosuppressants, their antitumor effects have not been...
17.
Kalim K, Yang J, Wunderlich M, Modur V, Nguyen P, Li Y, et al.
J Immunother Cancer
. 2022 Nov;
10(11).
PMID: 36427906
Background: Cancer immunotherapy has taken center stage in cancer treatment. However, the current immunotherapies only benefit a small proportion of patients with cancer, necessitating better understanding of the mechanisms of...
18.
Weng H, Huang F, Yu Z, Chen Z, Prince E, Kang Y, et al.
Cancer Cell
. 2022 Oct;
40(12):1566-1582.e10.
PMID: 36306790
N-Methyladenosine (mA) modification and its modulators play critical roles and show promise as therapeutic targets in human cancers, including acute myeloid leukemia (AML). IGF2BP2 was recently reported as an mA...
19.
Azhar M, Kincaid Z, Kesarwani M, Menke J, Schwieterman J, Ansari S, et al.
Blood Adv
. 2022 Aug;
7(8):1460-1476.
PMID: 36044389
Despite significant advancements in developing selective FMS-like tyrosine kinase 3 (FLT3) inhibitors, resistance to treatment is common even on continued therapy. Acquisition of on-target mutations or adaptation to MAPK, JAK2,...
20.
Tirtakusuma R, Szoltysek K, Milne P, Grinev V, Ptasinska A, Chin P, et al.
Blood
. 2022 Jul;
140(17):1875-1890.
PMID: 35839448
The fusion gene MLL/AF4 defines a high-risk subtype of pro-B acute lymphoblastic leukemia. Relapse can be associated with a lineage switch from acute lymphoblastic to acute myeloid leukemia, resulting in...